^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

MaaT033

i
Other names: MaaT033, pooled allogeneic fecal microbiotherapy
Associations
Trials
Company:
MaaT Pharma
Drug class:
Microbiome modulator
Associations
Trials
5ms
Enrollment closed
|
MaaT033
12ms
IASO: Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov)
P1, N=15, Recruiting, MaaT Pharma | Phase classification: P1b --> P1 | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Sep 2024
Phase classification • Trial completion date • Trial primary completion date
|
MaaT033
1year
Enrollment open
|
MaaT033
over1year
Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial) (clinicaltrials.gov)
P2b, N=387, Not yet recruiting, MaaT Pharma | Trial completion date: Oct 2026 --> Jan 2027 | Initiation date: Jun 2023 --> Sep 2023
Trial completion date • Trial initiation date
|
MaaT033
almost2years
RESTORATION OF GUT MICROBIOTA DIVERSITY WITH ORAL POOLED FECAL MICROBIOTHERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY: THE PHASE 1B CIMON TRIAL (EBMT 2023)
The CIMON study results show that MaaT033 is safe, well tolerated and effective for gut microbiota restoration in AML patients receiving IC and ATB. A Phase II trial is planned to evaluate MaaT033 in preventing alloHCT complications.
Clinical • P1 data • Gut Microbiota
|
IL2 (Interleukin 2) • TGFB1 (Transforming Growth Factor Beta 1)
|
MaaT033
2years
Restoration of Gut Microbiota Diversity with Oral Pooled Fecal Microbiotherapy in Acute Myeloid Leukemia Patients after Intensive Chemotherapy: The Phase 1b Cimon Trial (ASH 2022)
For IC, 20 patients received cytarabine associated with an anthracycline, 1 patient received azacytidine. Conclusion The CIMON study results show that MaaT033 is safe, well tolerated and effective for gut microbiota restoration in AML patients receiving IC and ATB. A Phase II/III trial is planned to evaluate MaaT033 in preventing allo-HSCT complications.
Clinical • P1 data
|
IL2 (Interleukin 2)
|
cytarabine • azacitidine • MaaT033